Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
MacroGenics, Inc. (NASDAQ: MGNX) has published new research in Blood Advances detailing the role of TP53 abnormalities in the response to flotetuzumab, an investigational therapy for acute myeloid leukemia (AML). The study indicates that patients with TP53 mutations benefit from flotetuzumab, especially those with primary induction failure (PIF) or early relapse (ER). MacroGenics plans to enroll up to 200 patients in a pivotal study, with interim results expected at an upcoming medical conference, further supporting its development strategy in this challenging patient population.
MacroGenics (MGNX) has published a manuscript in Molecular Cancer Therapeutics, detailing the preclinical development of MGC018, an antibody-drug conjugate targeting B7-H3 for solid tumors. The ADC shows promising antitumor activity and a favorable safety profile in preclinical models of various cancers. A Phase 1 dose expansion trial for MGC018 is currently recruiting patients with metastatic castration-resistant prostate cancer, triple-negative breast cancer, and non-small cell lung cancer. The company aims to provide updates on the study next year.
MacroGenics, Inc. (NASDAQ: MGNX) announced the publication of interim results from a Phase 1/2 trial of flotetuzumab, aimed at treating acute myeloid leukemia (AML). The trial enrolled 88 patients, revealing a 16.7% complete remission rate in those with primary induction failure or early relapse. Flotetuzumab, a bispecific DART molecule, effectively targets CD123 on leukemic cells and CD3 on T cells, leading to significant T-cell mediated responses. The company plans to expand its trial to 200 patients, with interim results expected later this year, highlighting potential for a pivotal study in this high-unmet-need population.
MacroGenics (Nasdaq: MGNX) announced a $15 million milestone payment triggered by the initiation of a Phase 3 clinical trial for retifanlimab in collaboration with Incyte. This trial evaluates safety and efficacy in treating metastatic non-small cell lung cancer (NSCLC). With this agreement, MacroGenics could receive up to $390 million in development milestones and $330 million in commercial milestones, along with tiered royalties of 15-24% on future sales. The partnership aims to advance retifanlimab across multiple cancer types.
MacroGenics (MGNX) announced promising clinical data from the Phase 1 trial of MGD019, a bispecific PD-1 × CTLA-4 DART molecule targeting advanced solid tumors. The trial showed that MGD019 was well-tolerated, with no dose-limiting toxicities reported. Of the 18 evaluable patients at doses ≥ 3.0 mg/kg, 4 objective responses were noted, including a complete response in metastatic castration-resistant prostate cancer. The company plans to expand the study in patients with microsatellite stable colorectal cancer and non-small cell lung cancer at a recommended Phase 2 dose of 6.0 mg/kg.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced participation in two investor conferences in August 2020. The BTIG Virtual Biotechnology Conference will feature one-on-one meetings and a fire-side chat on August 10 at 12:30 p.m. ET. The Wedbush PacGrow Healthcare Conference is set for August 12 at 8:35 a.m. ET, with similar one-on-one meetings and a corporate overview. Webcasts of both events will be available on the company's website for 30 days post-conference.
MacroGenics, Inc. (NASDAQ: MGNX) announced its financial results for Q2 2020, revealing a net loss of $46.9 million, compared to $31.8 million a year prior. Revenue reached $20.3 million, driven by a $12.0 million agreement with Boehringer Ingelheim. R&D expenses rose to $57.4 million, reflecting increased clinical trial costs. As of June 30, 2020, cash and marketable securities total $232.8 million, extending the company's cash runway into 2023. The company anticipates presenting additional clinical data for its investigational products in upcoming months.
MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its financial results for Q2 2020 after market hours on July 30, 2020. A conference call to discuss these results and recent corporate developments is scheduled for the same day at 4:30 p.m. ET. Interested participants can join by calling (877) 303-6253 (domestic) or (973) 409-9610 (international) using Conference ID 3236629. The call will be available for replay on the company's website for 30 days.
MacroGenics, Inc. (NASDAQ: MGNX) announced positive results from a Phase 2 study published in Lancet Oncology, showcasing the efficacy of margetuximab combined with pembrolizumab as a chemotherapy-free treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The study found an objective response rate (ORR) of 18% and a disease control rate (DCR) of 53% among treated patients. Notably, the ORR was 44% in patients with high HER2 and PD-L1 expression. The ongoing Phase 2/3 MAHOGANY trial aims to further evaluate this regimen as a first-line therapy.
MacroGenics, Inc. (NASDAQ: MGNX) has announced the hiring of Stephen Eck, M.D., Ph.D., as Senior Vice President, Clinical Development & Chief Medical Officer, effective July 1, 2020. Dr. Eck brings over 20 years of experience in oncology therapeutics from previous roles at Immatics US and Astellas Pharma, among others. This addition is expected to enhance MacroGenics' presence in clinical development. Ezio Bonvini, M.D., will resume his role as Chief Scientific Officer after overseeing clinical development on an interim basis.
FAQ
What is the current stock price of Macrogenics (MGNX)?
What is the market cap of Macrogenics (MGNX)?
